王若琳, 顾宁. 半乳糖凝集素-3在心力衰竭中作用的研究进展[J]. 实用临床医药杂志, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742
引用本文: 王若琳, 顾宁. 半乳糖凝集素-3在心力衰竭中作用的研究进展[J]. 实用临床医药杂志, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742
WANG Ruolin, GU Ning. Research progress in role of galectin-3 in heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742
Citation: WANG Ruolin, GU Ning. Research progress in role of galectin-3 in heart failure[J]. Journal of Clinical Medicine in Practice, 2022, 26(3): 130-133, 138. DOI: 10.7619/jcmp.20214742

半乳糖凝集素-3在心力衰竭中作用的研究进展

Research progress in role of galectin-3 in heart failure

  • 摘要: 心力衰竭(HF)是由多种心血管疾病引起的临床复杂综合征。目前, HF的高发病率及高死亡率是人类面临的重要健康问题。半乳糖凝集素-3(Gal-3)是近年来发现的新型生物标记物, 其被认为与心脏纤维化、心室重构及炎症反应密切相关,并影响HF的预后。本文对Gal-3在HF中作用的研究进展进行综述。

     

    Abstract: Heart failure (HF) is a complex clinical syndrome caused by various cardiovascular diseases. At present, the high morbidity and mortality of HF is important health problems that mankind face. Galectin-3(Gal-3) is a novel biomarker discovered in recent years, which is believed to be closely related to cardiac fibrosis, ventricular remodeling and inflammatory response, and may affect the prognosis of HF. This paper reviewed the research progress on the role of Gal-3 in HF.

     

/

返回文章
返回